Epinephrine Lidocaine HCL — Class II drug recall D-0535-2025
Completed recall by Imprimis NJOF, LLC, reported 2025-07-30, distributed nationwide. Sub-Potent Drug: Subpotent assay results during stability testing.
| Recall number | D-0535-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Completed |
| Voluntary or mandated | Voluntary |
| Recalling firm | Imprimis NJOF, LLC, Ledgewood, NJ, United States |
| Recall initiated | 2025-07-09 |
| Classified | 2025-07-21 |
| Reported by FDA | 2025-07-30 |
| Distributed | Nationwide (US) |
| Quantity | 6,880 vials |
| Reason classes | potency, specification failure |
| NDC | 71384-0641-01 |
| Lot numbers | 24DEC017 |
| Expiration dates | 2025-07-12 |
Product
Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01
Reason for recall
Sub-Potent Drug: Subpotent assay results during stability testing.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0535-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.